Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | PKM | P14618 | 1/20 | 0.60 |
| ▸ | GLA | P06280 | 1/20 | 0.56 |
| ▸ | APEX1 | P27695 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | STAT3 | P40763 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11999961 | 0.84 | KDM4E (0.74) | KDM4EALDH1A1MAPTPKMMAPK1 | |
| SCHEMBL5041916 | 0.82 | ALDH1A1 (0.60) | KDM4EALDH1A1MAPTPKMGLA | |
| SCHEMBL12002308 | 0.82 | ALDH1A1 (0.66) | KDM4EALDH1A1MAPTPKMRXFP1 | |
| SCHEMBL2797897 | 0.81 | ALDH1A1 (0.51) | KDM4EALDH1A1MAPTPKMRXFP1 | |
| SCHEMBL15709048 | 0.81 | KDM4E (1.00) | KDM4EALDH1A1GLAAPEX1MAPK1 | |
| SCHEMBL5044685 | 0.79 | PTGDR2 (0.46) | KDM4EMAPT | |
| SCHEMBL2795612 | 0.78 | ALDH1A1 (0.48) | KDM4EALDH1A1MAPTPKMRXFP1 | |
| SCHEMBL21027277 | 0.77 | GLA (0.64) | KDM4EALDH1A1MAPTPKMGLA | |
| SCHEMBL11192095 | 0.77 | KDM4E (0.67) | KDM4EALDH1A1GLAAPEX1 | |
| SCHEMBL5186838 | 0.74 | KDM4E (0.66) | KDM4EGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8524738-B2 | Quinolinones and quinoxalinones as antibacterial composition | TOYAMA CHEMICAL CO., LTD. (JP) | 2013-09-03 | — | — | US | disclosed |
| US-20120214990-A1 | QUINOLINONES AND QUINOXALINONES AS ANTIBACTERIAL COMPOSITION | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-08-23 | — | — | US | disclosed |
| EP-2468743-A1 | Nitrogen-containing bicyclic compounds useful as antibacterial agents | Toyama Chemical Co., Ltd. (JP) | 2012-06-27 | — | — | EP | disclosed |
| EP-1900732-A1 | NOVEL NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2008-03-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214990-A1 | QUINOLINONES AND QUINOXALINONES AS ANTIBACTERIAL COMPOSITION | NQO2, ASNS, NDUFS1 | KDM4E 2555/4885ALDH1A1 3142/4885MAPT 3361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.